GlassScriptPhysician profile
Christopher J Robbins
NPI 1437463916
$969.07
in general payments reported to CMS, 2019-2025
16 companies · $73.79 in 2025
The $73.79 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $50.19 · 2021: $278 · 2022: $317 · 2023: $79.27 · 2025: $73.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $293.71 | 2019-2025 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $168.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.77 | 2019-2022 | |
| Novo Nordisk INC | $87.46 | 2019-2022 | |
| Lilly USA, LLC | $63.18 | 2019-2022 | |
| Abbvie INC. | $56.00 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.10 | 2022 | |
| Pfizer INC. | $26.94 | 2020-2021 | |
| Phadia US INC. | $18.60 | 2023 | Immunocap |
| Biogen, INC. | $16.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.63 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.38 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.50 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.